Results 261 to 270 of about 766,818 (299)

PD-1–PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma

Blood, 2008
AbstractProgrammed death-1 (PD-1)–PD-1 ligand (PD-L) signaling system is involved in the functional impairment of T cells such as in chronic viral infection or tumor immune evasion. We examined PD-L expression in lymphoid cell lines and found that they were up-regulated on Hodgkin lymphoma (HL) and several T-cell lymphomas but not on B-cell lymphomas ...
Ryo, Yamamoto, Momoko, Nishikori, Toshio, Kitawaki, Tomomi, Sakai, Masakatsu, Hishizawa, Masaharu, Tashima, Tadakazu, Kondo, Katsuyuki, Ohmori, Masayuki, Kurata, Takamasa, Hayashi, Takashi, Uchiyama   +10 more
openaire   +2 more sources

Targeting PD-1

Science Signaling, 2018
Loss of an E3 ubiquitin ligase that targets PD-1 for degradation leads to inefficient antitumor responses by T cells.
openaire   +1 more source

Molecular Imaging of PD-1 Unveils Unknown Characteristics of PD-1 Itself by Visualizing “PD-1 Microclusters”

Programmed cell death-1 (PD-1) is one of the most famous coinhibitory receptors that are expressed on effector T cells to regulate their function. The PD-1 ligands, PD-L1 and PD-L2, are expressed by various cells throughout the body at steady state and their expression was further regulated within different pathological conditions such as tumor-bearing
Wataru, Nishi, Ei, Wakamatsu, Hiroaki, Machiyama, Ryohei, Matsushima, Yosuke, Yoshida, Tetsushi, Nishikawa, Hiroko, Toyota, Masae, Furuhata, Hitoshi, Nishijima, Arata, Takeuchi, Makoto, Suzuki, Tadashi, Yokosuka   +11 more
openaire   +2 more sources

FBXO38 Drives PD-1 to Destruction

Trends in Immunology, 2019
Aberrant expression of T cell-resident programmed cell death protein-1 (PD-1) is known to promote tumor progression. A recent study (Nature 2018;564:130-135) has now identified the E3 ubiquitin ligase FBXO38 as a crucial regulator of PD-1 protein turnover in T cells, providing a novel mechanism for potential use in cancer immunotherapy.
Taryn M, Serman, Michaela U, Gack
openaire   +2 more sources

PD-1/PD-L1 in Disease

Immunotherapy, 2017
Expression of PD-1 on T/B cells regulates peripheral tolerance and autoimmunity. Binding of PD-1 to its ligand, PD-L1, leads to protection against self-reactivity. In contrary, tumor cells have evolved immune escape mechanisms whereby overexpression of PD-L1 induces anergy and/or apoptosis of PD-1 positive T cells by interfering with T cell receptor ...
Kuol, Nyanbol, Stojanovska, Lily, Nurgali, Kulmira, Apostolopoulos, Vasso   +3 more
openaire   +3 more sources

Revisiting PD-1 signaling

Science Signaling, 2018
The protective effect of anti-PD1 therapy in cancer may not require the phosphatase Ptpn11.
openaire   +1 more source

Anti–PD-1 Therapy in Melanoma

Seminars in Oncology, 2015
Immune-regulatory mechanisms are used by cancer to hide from the immune system. Advances and in-depth understanding of the biology of melanoma and its interaction with the immune system have led to the development of some of antagonistic antibodies to the programmed death 1 pathway (PD-1) and one of its ligands, programmed death ligand 1 (PD-L1), which
Blanca, Homet Moreno, Giulia, Parisi, Lidia, Robert, Antoni, Ribas   +3 more
openaire   +2 more sources

MICRO-MELT PD#1

Alloy Digest, 2004
Abstract Micro-Melt PD#1 alloy is a powder metallurgically processed air hardening die steel with wear resistance better than AISI D2 while maintaining good toughness. This datasheet provides information on composition, physical properties, hardness, and elasticity.
openaire   +1 more source

Glucocorticoids and PD-1

Science Signaling, 2018
Signaling by the glucocorticoid receptor in NK cells induces expression of the checkpoint inhibitor PD-1 to prevent immunopathology.
openaire   +1 more source

Tumor Immunotherapy Directed at PD-1

New England Journal of Medicine, 2012
The treatment of cancer by harnessing immune responses has long been pursued. Efforts to turn on the immune system against cancers with inactivated tumor vaccines or intratumor injections of bacterial products to induce local inflammation and recruit an antitumor immune response have led to anecdotal successes. Increasing knowledge about how the immune
openaire   +2 more sources